- Home
- CRGY vs AKRO Comparison
CRGY vs AKRO Comparison
Compare CRGY & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGY
- AKRO
- Stock Information
- Founded
- CRGY 1986
- AKRO 2017
- Country
- CRGY United States
- AKRO United States
- Employees
- CRGY N/A
- AKRO N/A
- Industry
- CRGY Oil & Gas Production
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- CRGY Energy
- AKRO Health Care
- Exchange
- CRGY Nasdaq
- AKRO Nasdaq
- Market Cap
- CRGY 2.0B
- AKRO 2.0B
- IPO Year
- CRGY N/A
- AKRO 2019
- Fundamental
- Price
- CRGY $16.63
- AKRO $25.14
- Analyst Decision
- CRGY Buy
- AKRO Strong Buy
- Analyst Count
- CRGY 11
- AKRO 8
- Target Price
- CRGY $17.56
- AKRO $46.83
- AVG Volume (30 Days)
- CRGY 3.5M
- AKRO 842.7K
- Earning Date
- CRGY 03-03-2025
- AKRO 02-27-2025
- Dividend Yield
- CRGY 2.89%
- AKRO N/A
- EPS Growth
- CRGY 42.32
- AKRO N/A
- EPS
- CRGY 0.53
- AKRO N/A
- Revenue
- CRGY $2,713,358,000.00
- AKRO N/A
- Revenue This Year
- CRGY $25.83
- AKRO N/A
- Revenue Next Year
- CRGY $27.52
- AKRO N/A
- P/E Ratio
- CRGY $31.39
- AKRO N/A
- Revenue Growth
- CRGY 12.60
- AKRO N/A
- 52 Week Low
- CRGY $9.88
- AKRO $15.32
- 52 Week High
- CRGY $16.94
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- CRGY 74.43
- AKRO 41.89
- Support Level
- CRGY $12.90
- AKRO $21.34
- Resistance Level
- CRGY $16.94
- AKRO $28.94
- Average True Range (ATR)
- CRGY 0.41
- AKRO 1.38
- MACD
- CRGY 0.19
- AKRO -0.27
- Stochastic Oscillator
- CRGY 90.36
- AKRO 49.67
About CRGY Crescent Energy Company
Crescent Energy Co is an independent energy company with a portfolio of assets in key basins across the lower 48 states. The company maintains a diverse portfolio of assets in key basins across the United States, including the Eagle Ford, Rockies, Barnett, Permian, and Mid-Con. It seeks to deliver attractive risk-adjusted investment returns and predictable cash flows across cycles with a focus on operated oil and gas assets complemented by non-operated assets, mineral and royalty interests, and midstream infrastructure.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.